Following a year which saw a 143% increase in launched biosimilars in the US, here are three reasons why payers will drive adoption further in 2021.
John Fox
Advertisement
Articles by John Fox
Advertisement
Latest Updated Articles
- 3 Reasons US Payers Will Make 2021 a Banner Year for Biosimilars
Published: November 12th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
